Transcatheter Mitral-Valve Replacement in Surgical Valves and Rings

This new procedure provides an alternative for high-risk patients with failing bioprosthetic valves and annuloplasty rings.

Transcatheter mitral-valve replacement (TMVR) for degenerated mitral bioprostheses and failed annuloplasty rings is a less invasive alternative to repeat surgery, especially in patients at high surgical risk. Recently, the FDA approved a device for this new indication based on data from a U.S. national transcatheter valve therapy registry. Now, researchers have reported findings from an international registry involving 248 patients with previous mitral-valve surgery who were treated with TMVR in 25 centers between 2009 and 2017 (57% women; mean age, 72; Society of Thoracic Surgeons mean surgical risk score, 8.9%); 71% received valves-in-valves (VIVs) for degenerated bioprostheses, and 29% had valves-in-rings (VIRs) for failed annuloplasty r…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)